DK3411400T3 - Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet - Google Patents

Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet Download PDF

Info

Publication number
DK3411400T3
DK3411400T3 DK18701250.5T DK18701250T DK3411400T3 DK 3411400 T3 DK3411400 T3 DK 3411400T3 DK 18701250 T DK18701250 T DK 18701250T DK 3411400 T3 DK3411400 T3 DK 3411400T3
Authority
DK
Denmark
Prior art keywords
inhibitors
activity
treatment
inflammatory diseases
inflammatory
Prior art date
Application number
DK18701250.5T
Other languages
English (en)
Inventor
Renfeng Guo
Niels C Riedemann
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Application granted granted Critical
Publication of DK3411400T3 publication Critical patent/DK3411400T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18701250.5T 2017-04-03 2018-01-03 Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet DK3411400T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17164573 2017-04-03
EP17177657 2017-06-23
EP17189938 2017-09-07
PCT/EP2018/050146 WO2018184739A1 (en) 2017-04-03 2018-01-03 Treatment of inflammatory diseases with inhibitors of c5a activity

Publications (1)

Publication Number Publication Date
DK3411400T3 true DK3411400T3 (da) 2021-10-11

Family

ID=61024731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18701250.5T DK3411400T3 (da) 2017-04-03 2018-01-03 Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet

Country Status (17)

Country Link
US (4) US10376595B2 (da)
EP (3) EP3978523A1 (da)
JP (2) JP7486415B2 (da)
KR (1) KR20190138806A (da)
CN (1) CN111108118A (da)
AU (1) AU2018249310A1 (da)
CA (1) CA3058023A1 (da)
CL (1) CL2018002698A1 (da)
DK (1) DK3411400T3 (da)
ES (1) ES2893769T3 (da)
IL (1) IL261809B2 (da)
MX (1) MX2019011825A (da)
PL (1) PL3411400T3 (da)
SG (1) SG11201807998WA (da)
TW (2) TW202348249A (da)
WO (1) WO2018184739A1 (da)
ZA (1) ZA201906485B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP4218790B1 (en) 2015-12-16 2026-02-18 UCB Holdings, Inc. Modulators of complement activity
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3978523A1 (en) 2017-04-03 2022-04-06 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
CN111201241A (zh) * 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
EP4487915A3 (en) * 2018-11-30 2025-03-19 ChemoCentryx, Inc. Capsule formulations
EP3934675A2 (en) * 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
CN113784955B (zh) 2019-03-11 2025-02-14 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物
CA3137895A1 (en) * 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗c5a抗體
US20230340140A1 (en) * 2020-08-12 2023-10-26 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
MX2023004801A (es) * 2020-10-28 2023-05-10 Chemocentryx Inc Metodos de tratamiento de hidradenitis supurativa.
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
US12433657B2 (en) 2022-01-04 2025-10-07 B2M Medical, Inc. Planar-shaped thermal balloon for mesenteric fat reduction
CN116036233A (zh) * 2023-01-10 2023-05-02 中山大学附属第八医院(深圳福田) 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用
AU2024234172A1 (en) 2023-03-16 2025-08-28 Amgen Inc. Biomarkers for diagnosing hidradenitis suppurativa
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
WO2025037010A1 (en) * 2023-08-16 2025-02-20 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1727567T3 (da) 2004-02-12 2013-10-14 Archemix Llc Aptamer-terapeutiske midler nyttige i behandling af komplementrelaterede forstyrrelser
JP2007530454A (ja) 2004-03-26 2007-11-01 プロミックス・ピーティーワイ・リミテッド 補体C5a受容体モジュレーターを使用する神経疾患の治療
WO2008009062A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
RU2009110154A (ru) * 2006-08-22 2010-09-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
ME03043B (me) 2013-03-14 2018-10-20 Alnylam Pharmaceuticals Inc Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
DK2994488T3 (da) 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
JP6718379B2 (ja) * 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのC5aの阻害剤
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ, インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
WO2016209956A1 (en) 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
EP3978523A1 (en) 2017-04-03 2022-04-06 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
CN113784955B (zh) 2019-03-11 2025-02-14 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物

Also Published As

Publication number Publication date
EP4272821A2 (en) 2023-11-08
US20180282425A1 (en) 2018-10-04
CL2018002698A1 (es) 2018-12-07
TW202348249A (zh) 2023-12-16
PL3411400T3 (pl) 2021-12-20
EP4272821A3 (en) 2024-01-03
ES2893769T3 (es) 2022-02-10
IL261809A (en) 2018-11-29
JP7486415B2 (ja) 2024-05-17
US11890349B2 (en) 2024-02-06
JP2020515643A (ja) 2020-05-28
CA3058023A1 (en) 2018-10-11
US10376595B2 (en) 2019-08-13
US20210046191A1 (en) 2021-02-18
TW201836641A (zh) 2018-10-16
IL261809B1 (en) 2023-12-01
US11464868B2 (en) 2022-10-11
EP3978523A1 (en) 2022-04-06
TWI826364B (zh) 2023-12-21
EP3411400A1 (en) 2018-12-12
SG11201807998WA (en) 2018-12-28
JP2022176946A (ja) 2022-11-30
ZA201906485B (en) 2021-08-25
MX2019011825A (es) 2020-12-11
US20200061202A1 (en) 2020-02-27
AU2018249310A1 (en) 2019-10-17
EP3411400B1 (en) 2021-09-22
US20180280530A1 (en) 2018-10-04
IL261809B2 (en) 2024-04-01
KR20190138806A (ko) 2019-12-16
WO2018184739A1 (en) 2018-10-11
CN111108118A (zh) 2020-05-05
US11273225B2 (en) 2022-03-15

Similar Documents

Publication Publication Date Title
IL261809A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
IL271074A (en) Treatment of inflammatory diseases with c5a activity inhibitors
DK4154882T3 (da) Behandling af amyotrofisk lateralsklerose med pridopidin
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3548061T3 (da) Behandling af neurologiske sygdomme
IL283069A (en) Methods for administering corticosteroids
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
LT3307267T (lt) Išsėtinės sklerozės gydymas
DK3250600T3 (da) Behandling af autoimmune lidelser med cd154-antistoffer
IL257764B (en) Methods for treatment of diseases
DK3237621T3 (da) Varianter af human alpha-galactosidase
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
PL3661510T3 (pl) Sposoby leczenia zmian zachowania
IL254825A0 (en) Methods of treatment with taselisib
PL3458067T3 (pl) Leczenie chorób neurologicznych